Lacutamab in patients with relapsed and/or refractory mycosis fungoides: Results from the TELLOMAK phase 2 trial.

被引：0

作者：

Porcu, Pierluigi

Bagot, Martine

Ram-Wolff, Caroline

Kim, Youn H.

Huen, Auris

Dalle, Stephane

Poligone, Brian

Mehta-Shah, Neha

Modeste, Anne Benedicte Duval

Zinzani, Pier Luigi

Woei-A-Jin, Feng Jung Sherida Harriette

Eigentler, Thomas

Combalia, Andrea

Sokol, Lubomir

Battistella, Maxime

Gru, Alejandro

Teisserenc, Helene Moins

Viotti, Julien

Paiva, Christine

Chammard, Agnes Boyer

机构：

[1] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA USA

[2] Univ Paris Cite, Hop St Louis, INSERM, U976, Paris, France

[3] Stanford Univ, Dept Dermatol, Multidisciplinary Cutaneous Lymphoma Program, Stanford, CA USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX USA

[5] Hosp Civils Lyon, Dept Dermatol, Pierre Benite, France

[6] Rochester Skin Lymphoma Med Grp, PLLC, Fairport, NY USA

[7] Washington Univ, Dept Med, Div Oncol, St Louis, MO USA

[8] CHU Rouen, Hop Charles Nicolle, Dept Dermatol, Rouen, France

[9] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[10] Univ Ziekenhuis Leuven, Dept Gen Med Oncol, Leuven, Belgium

[11] Charite Univ Med Berlin, Dept Dermatol Venerol & Allergol, Berlin, Germany

[12] Hosp Clin Barcelona, Dept Dermatol, Barcelona, Spain

[13] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[14] Univ Paris Cite, Dept Pathol, Hop St Louis, INSERM U976, Paris, France

[15] Univ Virginia, Dept Pathol, Sch Med, Charlottesville, VA USA

[16] Univ Paris Cite, Hop St Louis, AP HP, Hematol Lab,INSERM 1160, Paris, France

[17] Innate Pharma, Marseille, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7082

引用

页数：1

共 50 条

[21] Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
Richardson, Paul G.
Bensinger, William I.
Huff, Carol Ann
Costello, Caitlin L.
Lendvai, Nikoletta
Berdeja, Jesus G.
Anderson, Larry D., Jr.
Siegel, David S.
Lebovic, Daniel
Jagannath, Sundar
Laubach, Jacob P.
Stockerl-Goldstein, Keith E.
Kwei, Long
Clow, Fong
Elias, Laurence
Salman, Zeena
Graef, Thorsten
Bilotti, Elizabeth
Vij, Ravi
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (06) : 821 - 830
[22] A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
Richardson, Paul G.
Xie, Wanling
Jagannath, Sundar
Jakubowiak, Andrzej
Lonial, Sagar
Raje, Noopur S.
Alsina, Melissa
Ghobrial, Irene M.
Schlossman, Robert L.
Munshi, Nikhil C.
Mazumder, Amitabha
Vesole, David H.
Kaufman, Jonathan L.
Colson, Kathleen
McKenney, Mary
Lunde, Laura E.
Feather, John
Maglio, Michelle E.
Warren, Diane
Francis, Dixil
Hideshima, Teru
Knight, Robert
Esseltine, Dixie-Lee
Mitsiades, Constantine S.
Weller, Edie
Anderson, Kenneth C.
BLOOD, 2014, 123 (10) : 1461 - 1469
[23] Phase II trial of all-trans retinoic acid (ATRA) in the treatment of relapsed/refractory mycosis fungoides/sezary syndrome (MF/SS).
Siegel, RS
Martone, B
Guitart, J
Samuelson, E
Rosen, ST
Kuzel, TM
BLOOD, 1999, 94 (10) : 97A - 97A
[24] Dexamethasone, cytarabine and oxaliplatin (DHAX) in relapsed or refractory non-Hodgkin's lymphoma patients: Results of an ongoing phase II trial.
Chau, I
Cunningham, D
Hill, M
Catovsky, D
BLOOD, 2000, 96 (11) : 140A - 140A
[25] Clinical efficacy of lenalidomide {Revlimid®} in patients with relapsed or refractory chronic lymphocytic leukemia (CLL):: Updated results of a phase II clinical trial.
Chanan-Khan, Asher Alban
Miller, Kena C.
Musial, Laurie
Padmanabhan, Swaminathan
Lawrence, David
Bernstein, Zale P.
Takeshita, Kenichi
Spaner, David
Byrne, Catriona
Chrystal, Cynthia
Czuczman, Myron S.
BLOOD, 2006, 108 (11) : 95A - 95A
[26] Treatment of relapsed/refractory, and advanced stage of mycosis fungoides with brentuximab vedotin (BV): an experience from Kuwait
Hamed, Rasha
Hamadah, Abdulaziz
Alshemmari, Salem
Abdulazez, Osama
Nanda, Arti
Pinto, Karen
Al Lafi, Atlal
Rajy, Jihan
Al-Sabah, Hamoud
EUROPEAN JOURNAL OF CANCER, 2023, 190 : S47 - S47
[27] Bendamustine in combination with thalidomide and prednisolone (BPT) in patients with refractory or relapsed multiple myeloma (MM): Preliminary results of a phase I clinical trial.
Poenisch, W
Rozanski, M
Leiblein, S
Goldschmidt, H
Wegner, A
Niederwieser, D
BLOOD, 2004, 104 (11) : 307B - 307B
[28] PHARMACOKINETICS OF SELINEXOR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: A PHASE I TRIAL.
Badawi, M.
Walker, A.
Mims, A.
Vasu, S.
Blum, W.
Klisovic, R.
Bhatnagar, B.
Phelps, M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S51 - S51
[29] Plaque-Phase Mycosis Fungoides Treated with Photodynamic Therapy: Results from 12 Patients
Fernandez-Guarino, M.
Harto, A.
Perez-Garcia, B.
Montull, C.
De las Heras, E.
Jaen, P.
ACTAS DERMO-SIFILIOGRAFICAS, 2010, 101 (09): : 785 - 791
[30] Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial
Fukuhara, Noriko
Kato, Koji
Goto, Hideki
Takeshi, Tajima
Kawaguchi, Mayu
Tokushige, Kota
Akashi, Koichi
Teshima, Takanori
Harigae, Hideo
Schuster, Stephen J.
Thieblemont, Catherine
Dreyling, Martin
Fowler, Nathan
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (02) : 251 - 259

← 1 2 3 4 5 →